A novel modular protein adapter platform, named G-Link, was showcased at the American Society of Gene and Cell Therapy (ASGCT) meeting. Developed in collaboration with Menachem Rubenstein, PhD, of the Weizmann Institute, the technology enables drug developers to cap and retarget existing lentiviral vectors for in vivo delivery. This plug-and-play approach could streamline the production and administration of CAR-T cell therapies, moving away from complex ex vivo manufacturing.
The G-Link platform functions as a molecular adapter that modifies the tropism of lentiviral vectors, directing them specifically to target cells within the body. By capping the vector with a protein-based adapter, the system can be reprogrammed to recognize different cell surface markers. This potentially reduces the need for patient-specific cell engineering and shortens manufacturing timelines from weeks to days.
As a preclinical-stage technology, G-Link has not yet entered human clinical trials. The platform is designed to be compatible with existing lentiviral vector manufacturing processes, which may simplify regulatory approval pathways. The next steps involve validating the system in additional animal models and initiating discussions with regulatory agencies for first-in-human studies.
The company behind the platform has not disclosed specific financial terms or a valuation, but the approach targets a multi-billion-dollar CAR-T market currently dominated by ex vivo products. Analysts note that if successfully translated, G-Link could democratize access to CAR-T therapies by reducing costs and enabling outpatient administration. However, it faces stiff competition from other in vivo delivery technologies, such as lipid nanoparticles and adeno-associated virus vectors.
Patient access to this technology remains speculative at this early stage. If clinical development proceeds, the platform could offer a more scalable and less logistically burdensome manufacturing model. Experts caution that in vivo vector safety and long-term expression control remain critical challenges that must be addressed before broader adoption becomes feasible.